Related Experiment Video
Updated: May 19, 2026
08:04
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
Reimbursement challenges with cancer immunotherapeutics
1koudrine@hotmail.com
Human Vaccines & Immunotherapeutics
|August 17, 2012
Summary
Cancer vaccine developers must analyze cost-effectiveness and engage stakeholders early. Early patient-reported outcomes data collection is crucial for demonstrating value and facilitating market access for new immunotherapies.
Area of Science:
- Oncology
- Health Economics
- Immunotherapy
Background:
- Cancer vaccine development requires expertise in immunology, clinical trials, and economic analysis.
- EU health technology bodies evaluate new therapies based on clinical and economic value, considering budget uncertainties.
- Market access for novel oncology treatments often involves risk-sharing agreements with payers.
Purpose of the Study:
- To review the methodologies used by EU health technology bodies for appraising new cancer therapies.
- To highlight the importance of economic and clinical value assessment in market access.
- To provide insights into risk-sharing agreements for oncology treatments.
Main Methods:
- Review of methodologies employed by European health technology assessment (HTA) bodies.
- Analysis of economic and clinical value appraisal frameworks.
- Examination of risk-sharing agreements in the EU market for oncology treatments.
Main Results:
- New oncology treatments increasingly access the EU market via risk-sharing agreements.
- Early collection of patient-reported outcomes (PROs) can enhance the projected clinical and economic value of immunotherapies.
- Proactive engagement with stakeholders, including patient organizations, physicians, and payers, is vital for market access.
Conclusions:
- Cancer vaccine developers need to integrate economic evaluation and stakeholder engagement into their strategies.
- Demonstrating additional clinical and economic value through early PRO collection is essential.
- Facilitating market access requires early and continuous interaction with all relevant parties.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...